Asahi shares mark weekly slide after cyberattack halts production
MINNEAPOLIS - Bio-Techne Corporation (NASDAQ:TECH), a life sciences company with a robust 66.5% gross profit margin and strong financial health according to InvestingPro analysis, announced new developments in its spatial biology portfolio that enable simultaneous RNA and protein detection on the same tissue section, according to a press release statement issued Friday.
The company’s RNAscope ISH technology and Lunaphore COMET platform allow researchers to detect RNA and protein biomarkers together, potentially bridging translational research and clinical applications.
Recent scientific investigations presented this fall explore the diagnostic potential of these technologies, including the use of RNAscope for assessing B-cell clonality and COMET for spatial profiling of lymphoid malignancies using a 21-plex seqIF panel.
Bio-Techne is showcasing these innovations at the National Society of Histotechnology Convention taking place September 26-30 in Long Beach, California. The company’s Advanced Cell Diagnostics and Lunaphore divisions are exhibiting at the event.
Presentations at the convention include discussions on RNAscope applications in routine anatomic pathology and its potential insights for B-cell clonality assessment. Additionally, researchers will present findings on using COMET technology for improving diagnosis of lymphoid malignancies.
"We are thrilled by the progress we’ve made in advancing traditional in situ hybridization," said Dr. Matt McManus, President of the Diagnostics and Spatial Biology Segment of Bio-Techne, in the statement.
The company noted that the RNAscope probe for IGLL5 is an Analyte Specific Reagent, and both RNAscope and COMET are for research use only and not for diagnostic procedures.
Bio-Techne reported generating over $1.2 billion in net sales in fiscal 2025 and employs approximately 3,100 people worldwide. The company maintains a healthy financial position with a current ratio of 3.46, indicating strong liquidity. Based on InvestingPro’s Fair Value analysis, the stock appears to be trading near its fair value. InvestingPro subscribers have access to 10 additional key insights about Bio-Techne’s financial outlook and detailed valuation metrics through the platform’s comprehensive Pro Research Report.
In other recent news, Bio-Techne Corp reported its fourth-quarter earnings for fiscal year 2025, exceeding analysts’ expectations. The company achieved an adjusted earnings per share (EPS) of $0.53, surpassing the projected $0.50. Revenue also came in slightly higher than anticipated at $317 million, compared to the forecasted $315.54 million. These results highlight Bio-Techne’s ability to perform above market predictions despite broader market concerns and sector-specific challenges. While the company’s stock experienced a decline in pre-market trading, this was not directly related to its earnings performance. Analyst firms have not made any recent upgrades or downgrades following the earnings report. Investors continue to monitor Bio-Techne’s performance in light of these recent developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.